About Ideaya Biosciences
Ideaya Biosciences (NASDAQ:IDYA) is a dynamic bio-pharmaceutical company dedicated to the discovery and development of targeted therapeutics for cancer. At the heart of their operations is a commitment to leveraging cutting-edge technologies and scientific approaches to address unmet needs in the oncology space. Ideaya Biosciences focuses on precision medicine, aiming to create treatments that can target specific genetic mutations and pathways that drive cancer growth. Their projects span a range of cancers, with an emphasis on developing both small molecule and immuno-oncology agents. The company's objectives are firmly rooted in the advancement of their clinical pipeline, aiming to progress through various stages of clinical trials efficiently, with the ultimate goal of bringing innovative cancer therapies to patients who need them most.
Snapshot
Operations
Produtos e/ou serviços de Ideaya Biosciences
- A precision medicine focused on targeting patient populations with genetically defined cancers through synthetic lethality, including MAT2A for MTAP-deletion tumors.
- An immuno-oncology program aiming to enhance anti-tumor activity by targeting the immune system's ability to fight cancer.
- Development of a novel inhibitor for the treatment of solid tumors, focusing on the role of PARG in DNA repair.
- A partnership project to discover and develop targeted therapies across various oncology indications, leveraging synthetic lethality and immuno-oncology platforms.
- Collaboration on the development of a first-in-class therapy targeting GSK in specific cancer types, aimed at inhibiting tumor growth and progression.
- An advanced preclinical stage project focused on developing inhibitors targeting the Werner syndrome protein (WRN) helicase in cancers with microsatellite instability.
equipe executiva do Ideaya Biosciences
- Mr. Yujiro S. HataFounder, President, CEO & Director
- Mr. Andres Ruiz Briseno CPAChief Accounting Officer
- Dr. Michael A. White Ph.D.Chief Scientific Officer
- Dr. Darrin M. Beaupre M.D., Ph.D.Chief Medical Officer
- Mr. Stuart C. DormanChief Commercial Officer
- Dr. Joshua Bleharski Ph.D.Chief Financial Officer
- Dr. Paul A. Barsanti Ph.D.Chief Technology Officer
- Mr. Douglas B. SnyderSenior VP & General Counsel
- Ms. Francine ZelayaVice President & Head of Human Resources
- Mr. Mick O'QuigleyChief of Staff & Clinical Development